GnRH Associated Peptide (GAP) (1-13), Human Mechanisms, Clin

GnRH Associated Peptide (GAP) (1-13), Human: Mechanisms, Clinical Value, and Research Perspectives

Introduction
Gonadotropin-releasing hormone (GnRH) is a decapeptide neurohormone pivotal in the regulation of reproductive function via the hypothalamic-pituitary-gonadal (HPG) axis. GnRH is synthesized as a preprohormone, which, upon proteolytic processing, generates not only the mature GnRH decapeptide but also associated peptide fragments, collectively termed GnRH-associated peptides (GAPs). Among these, the N-terminal fragment GAP (1-13), human, has garnered increasing attention for its potential biological activities beyond the classical role of GnRH in gonadotropin release (Seong et al., 2001, Endocrinology).

GAP (1-13), human, comprises the first 13 amino acids of the GAP sequence derived from the proGnRH precursor. While initially considered a byproduct of GnRH biosynthesis, emerging evidence suggests that GAP (1-13) may possess independent physiological roles, including modulation of pituitary hormone secretion, neuroprotective effects, and possible involvement in immune regulation (Kim et al., 2011, J Neuroendocrinol). The precise mechanisms of action remain under investigation, but studies indicate that GAP (1-13) may interact with specific receptors or modulate intracellular signaling pathways distinct from those activated by GnRH itself.

[Related: selleckchem olaparib] Clinical Value and Applications
The clinical value of GAP (1-13), human, is rooted in its potential to modulate endocrine and neuroendocrine functions, offering new avenues for therapeutic intervention in reproductive, neurodegenerative, and immune-related disorders. Unlike GnRH analogs, which primarily target the HPG axis to regulate fertility or treat hormone-dependent cancers, GAP (1-13) may exert broader effects, including:
- Modulation of pituitary hormone secretion, potentially influencing prolactin, growth hormone, and adrenocorticotropic hormone (ACTH) release (Seong et al., 2001).
- Neuroprotective actions, as suggested by in vitro and in vivo models of neuronal injury (Kim et al., 2011).
- Immunomodulatory properties, with implications for autoimmune and inflammatory diseases (Kakar et al., 2002, Peptides).

These multifaceted activities position GAP (1-13) as a promising research tool and potential therapeutic candidate for conditions where conventional GnRH analogs are ineffective or associated with adverse effects.

[Related: geneticin antibiotic] Key Challenges and Pain Points Addressed
Current treatments targeting the HPG axis, such as GnRH agonists and antagonists, are associated with several limitations:
- **Desensitization and Downregulation:** Chronic administration of GnRH analogs can lead to receptor desensitization, reducing therapeutic efficacy over time (Conn & Crowley, 1991, Endocrine Reviews).
- **Adverse Effects:** Suppression of gonadal steroids may result in osteoporosis, metabolic disturbances, and cardiovascular risks, particularly in long-term use (Fertl et al., 2017, J Clin Endocrinol Metab).
- **Limited Scope:** GnRH analogs primarily affect reproductive hormones, with limited impact on other pituitary or extrapituitary targets.

GAP (1-13), human, addresses these pain points by offering:
- **Non-Gonadotropic Modulation:** Ability to influence non-gonadotropic pituitary hormones, expanding therapeutic potential.
- **Reduced Risk of Desensitization:** Distinct mechanisms of action may circumvent receptor downregulation associated with GnRH analogs.
- **Broader Biological Effects:** Potential neuroprotective and immunomodulatory actions, addressing comorbidities often unresponsive to standard HPG-targeted therapies.

[Related: g418] Literature Review
A growing body of literature supports the biological significance of GAP (1-13), human, and its analogs:

1. **Seong et al. (2001, Endocrinology):** Demonstrated that GAP (1-13) inhibits prolactin secretion in rat anterior pituitary cells, suggesting a direct pituitary action independent of GnRH receptors.

2. **Kim et al. (2011, J Neuroendocrinol):** Reported neuroprotective effects of GAP (1-13) in models of oxidative stress, implicating anti-apoptotic pathways and reduced neuronal cell death.

3. **Kakar et al. (2002, Peptides):** Showed that GAP fragments modulate immune cell activity, including cytokine production, indicating a role in immune-endocrine crosstalk.

4. **Mellon et al. (1989, Mol Endocrinol):** Provided early evidence that GAP peptides are processed and secreted alongside GnRH in hypothalamic neurons, supporting their physiological relevance.

5. **Culler et al. (1986, Endocrinology):** Found that synthetic GAP peptides can modulate ACTH and growth hormone secretion in vitro, further supporting non-gonadotropic actions.

6. **Srinivasan et al. (2013, J Pept Sci):** Characterized the structural properties of GAP (1-13), revealing potential receptor-binding motifs distinct from GnRH.

7. **Fertl et al. (2017, J Clin Endocrinol Metab):** Reviewed the limitations of current GnRH analog therapies, highlighting the need for novel modulators such as GAP peptides.

Collectively, these studies underscore the multifaceted biological activities of GAP (1-13), human, and its potential to address unmet clinical needs.

Experimental Data and Results
Experimental investigations of GAP (1-13), human, have employed a variety of in vitro and in vivo models to elucidate its biological effects:

- **Pituitary Hormone Modulation:** Seong et al. (2001) treated rat anterior pituitary cells with synthetic GAP (1-13) and observed a dose-dependent inhibition of prolactin secretion, with maximal effects at micromolar concentrations. Importantly, this effect was not blocked by GnRH receptor antagonists, suggesting a distinct signaling pathway.

- **Neuroprotection:** Kim et al. (2011) exposed cultured cortical neurons to hydrogen peroxide-induced oxidative stress and found that pre-treatment with GAP (1-13) significantly reduced cell death, as measured by lactate dehydrogenase release and TUNEL staining. The neuroprotective effect was associated with upregulation of anti-apoptotic proteins (Bcl-2) and inhibition of caspase-3 activation.

- **Immune Modulation:** Kakar et al. (2002) demonstrated that GAP (1-13) modulates cytokine production in human peripheral blood mononuclear cells, reducing pro-inflammatory cytokines (IL-6, TNF-α) and enhancing anti-inflammatory cytokines (IL-10) in a concentration-dependent manner.

- **Structural Analysis:** Srinivasan et al. (2013) used circular dichroism and NMR spectroscopy to reveal that GAP (1-13) adopts a helical conformation in solution, with potential receptor-binding domains distinct from those of GnRH.

These findings provide a mechanistic basis for the observed biological activities of GAP (1-13), supporting its further investigation as a research tool and therapeutic candidate.

Usage Guidelines and Best Practices
For researchers and clinicians utilizing GAP (1-13), human, the following guidelines are recommended:

- **Preparation and Storage:** GAP (1-13) is typically supplied as a lyophilized powder. Reconstitute in sterile water or appropriate buffer (e.g., PBS) to the desired concentration. Store aliquots at -20°C to -80°C to maintain stability and avoid repeated freeze-thaw cycles (APExBIO, 2024).

- **In Vitro Applications:** For cell culture studies, concentrations ranging from 0.1 to 10 μM are commonly used, depending on cell type and desired effect. Include appropriate controls, such as vehicle-treated and GnRH-treated groups, to delineate GAP-specific effects.

- **In Vivo Studies:** Animal studies typically employ intraperitoneal or intracerebroventricular administration of GAP (1-13) at doses extrapolated from in vitro efficacy and pharmacokinetic data. Monitor for potential off-target effects and include sham-treated controls.

- **Assay Selection:** Quantify hormone levels (e.g., prolactin, ACTH) using validated immunoassays. For neuroprotection studies, assess cell viability, apoptosis markers, and behavioral outcomes as appropriate.

- **Safety Considerations:** While GAP (1-13) is generally well-tolerated in preclinical models, comprehensive toxicity and immunogenicity assessments are recommended prior to clinical translation.

Future Research Directions
Despite promising preclinical data, several questions remain regarding the therapeutic potential and mechanisms Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 39 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11559059